Prevention of postmenopausal osteoporosis

Area of Science:

• Endocrinology
• Gerontology
• Bone Metabolism

Background:

• Osteoporosis treatment is often unsatisfactory, making prevention the preferred strategy.
• Accurate identification of individuals at high risk for osteoporotic fractures remains a challenge.
• Postmenopausal bone loss significantly increases fracture risk.

Purpose of the Study:

• To outline a strategy for identifying postmenopausal women at increased risk of osteoporosis.
• To discuss the role of estrogen therapy in preventing bone loss.
• To consider the benefits and potential side effects of hormone therapy for osteoporosis prevention.

Main Methods:

• Utilizing risk assessment tools to evaluate fracture likelihood.
• Incorporating bone mass measurements (bone density scans) in postmenopausal patients.
• Reviewing the efficacy of estrogen and progestogen therapy for bone health.

Main Results:

• Judicious risk assessment combined with bone mass measurements can identify at-risk postmenopausal women.
• Estrogen therapy is the most effective agent for preventing postmenopausal bone loss.
• Adding a progestogen may enhance estrogen's bone-sparing effects by stimulating bone formation.

Conclusions:

• Estrogen therapy, when not contraindicated, is recommended for postmenopausal women identified at increased risk of osteoporosis.
• Combined estrogen-progestogen therapy may offer additional benefits for bone formation.
• The overall benefits and risks of hormone therapy must be carefully considered for each patient.